Max India (MAXIND) Fundamentals 2026 — Revenue Analysis | SniperIQ
Max India (MAXIND) is a India-listed Healthcare company in Medical - Care Facilities with a market capitalization of ₹846 Crore, trading at ₹160.80 on the NSE. This SniperIQ fundamentals page covers Max India's valuation, profitability (net margin -63.9%), revenue (₹191 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Max India's market cap?
Max India (MAXIND) has a market capitalization of approximately ₹846 Crore, trading at ₹160.80 on the NSE. Market cap moves with the live share price.
What is Max India's P/E ratio?
Max India's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Max India?
Max India runs a net profit margin of -63.9%, a gross margin of 37.2%, and an operating margin of -68.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Max India generate?
Max India reported revenue of ₹191 Crore for fiscal year 2026, with net income of -₹122 Crore and earnings per share (EPS) of -23.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Max India pay a dividend?
Max India does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Max India financially healthy?
Max India carries a debt-to-equity ratio of 0.24x and a current ratio of 2.35x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Max India a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Max India (MAXIND) the key facts are: market cap ₹846 Crore, revenue ₹191 Crore, 52-week range 120-241.57. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Max India's full fundamentals live
Get Max India's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.